SCHEDULE: Anson Funds Discloses 9.3% Stake in NRX Pharma
Beneficial Ownership Disclosure
Anson Funds Management LP and related entities have disclosed a 9.3% beneficial ownership stake in NRX Pharmaceuticals, Inc. common stock.
Summary
- Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam collectively beneficially own 1,604,975 shares of NRX Pharmaceuticals, Inc. Common Stock.
- This ownership represents 9.3% of the outstanding shares of Common Stock.
- The percentage is calculated based on 17,289,192 shares of Common Stock issued and outstanding, as reported in NRX Pharmaceuticals' Form 10-Q filed on May 15, 2025.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing indicates a significant passive investment by Anson Funds, a known investment manager, in a pharmaceutical company. Such disclosures are common for institutional investors accumulating stakes in publicly traded companies, reflecting their investment strategy rather than direct operational involvement.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
- Management: Awareness of a large passive shareholder, though no direct impact on control is indicated.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of Issuer's Quarterly Report on Form 10-Q, which reported 17,289,192 shares outstanding. |
| 06/30/2025 | Date of event which requires filing of this statement (reporting period end). |
| 08/14/2025 | Filing date of the Schedule 13G Amendment No. 1. |
Keywords
NRX Pharmaceuticals, Anson Funds, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.